Literature DB >> 33466133

Effect of traditional Chinese medicine (TCM) on survival, quality of life, and immune function in patients with ovarian carcinoma: A protocol for systematic review and meta analysis.

Shuxia Ge1, Qianqian Xing2, Anqi Zhang3, Yucui Wang1.   

Abstract

BACKGROUND: Traditional Chinese medicine (TCM) has been widely applied as promising adjunctive drugs for ovarian carcinoma (OC) in China and other Asian countries. However, its exact clinical efficacy and safety is still not well investigated. In this study, we aimed to summarize the efficacy of TCM on survival, quality of life (QoL), and immune function in patients with OC through the meta-analysis.
METHODS: Relevant clinical trials of TCM for the treatment OC patients will be searched in Cochrane Library, Web of Science, Google Scholar, PubMed, Medline, Embase, China Scientific Journal Database, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, and Wanfang Database from their inception to November 2020. Two researchers will perform data extraction and risk of bias assessment independently. The clinical outcomes, including overall survival (OS), QoL, immune function, tumor markers, and adverse events, were systematically evaluated by using Review Manager 5.3 and Stata 14.0 statistical software.
RESULTS: The results of this study will provide high-quality evidence for the effect of TCM on survival, QoL and immune function in patients with OC.
CONCLUSION: The conclusions of this meta-analysis will be published in a peer-reviewed journal, and draw an objective conclusion of the efficacy of TCM on survival, QoL, and immune function in patients with OC. TRIAL REGISTRATION NUMBER: INPLASY2020110104.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33466133      PMCID: PMC7808448          DOI: 10.1097/MD.0000000000023904

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  38 in total

1.  Effects of Traditional Chinese Medicine in Treatment of Breast Cancer Patients After Mastectomy: A Meta-Analysis.

Authors:  Wei Wang; Lin Xu; Chaoyan Shen
Journal:  Cell Biochem Biophys       Date:  2015-04       Impact factor: 2.194

2.  Systematic reviews of the effectiveness of quality improvement strategies and programmes.

Authors:  J Grimshaw; L M McAuley; L A Bero; R Grilli; A D Oxman; C Ramsay; L Vale; M Zwarenstein
Journal:  Qual Saf Health Care       Date:  2003-08

3.  Aqueous extract of herba Scutellaria barbatae, a chinese herb used for ovarian cancer, induces apoptosis of ovarian cancer cell lines.

Authors:  C Bethan Powell; Philip Fung; Jim Jackson; Joe Dall'Era; Debra Lewkowicz; Isaac Cohen; Karen Smith-McCune
Journal:  Gynecol Oncol       Date:  2003-11       Impact factor: 5.482

4.  An in vitro and in vivo investigation of the antimetastatic effects of a Chinese medicinal decoction, erxian decoction, on human ovarian cancer models.

Authors:  Ellie S M Chu; Stephen C W Sze; Ho P Cheung; Qing Liu; Tzi B Ng; Yao Tong
Journal:  Integr Cancer Ther       Date:  2012-12-12       Impact factor: 3.279

Review 5.  Ovarian cancer: an overview.

Authors:  Michelle A Roett; Patricia Evans
Journal:  Am Fam Physician       Date:  2009-09-15       Impact factor: 3.292

6.  Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial.

Authors:  B K Piao; Y X Wang; G R Xie; U Mansmann; H Matthes; J Beuth; H S Lin
Journal:  Anticancer Res       Date:  2004 Jan-Feb       Impact factor: 2.480

Review 7.  Ovarian cancer: risk factors, treatment and management.

Authors:  Carolyn Rooth
Journal:  Br J Nurs       Date:  2013 Sep 12-25

8.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.

Authors:  Larissa Shamseer; David Moher; Mike Clarke; Davina Ghersi; Alessandro Liberati; Mark Petticrew; Paul Shekelle; Lesley A Stewart
Journal:  BMJ       Date:  2015-01-02

9.  Fuling Granule, a Traditional Chinese Medicine Compound, Suppresses Cell Proliferation and TGFβ-Induced EMT in Ovarian Cancer.

Authors:  Fangfang Tao; Shanming Ruan; Wenhong Liu; Libin Wang; Yang Xiong; Minhe Shen
Journal:  PLoS One       Date:  2016-12-30       Impact factor: 3.240

10.  Guizhi Fuling Wan, a Traditional Chinese Herbal Formula, Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Inactivation of the PI3K/AKT/mTOR Pathway.

Authors:  Li Han; Xiaojuan Guo; Hua Bian; Lei Yang; Zhong Chen; Wenhua Zang; Jingke Yang
Journal:  Evid Based Complement Alternat Med       Date:  2016-05-18       Impact factor: 2.629

View more
  3 in total

1.  Effect of Psychological Intervention Combined with Dietary Guidance on Quality of Life and Long-Term Efficacy of Bushen Quyu Decoction in Treatment of Patients with Advanced Ovarian Cancer.

Authors:  Dan Liu; Guangwen Shi; Chao Yin; Zhendong Liu; Aixia Yang
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-25       Impact factor: 2.629

2.  Diagnostic Value of Serum Markers Combined with TVCDS in Ovarian Cancer Patients Treated with Bushen Yiqi Quyu Prescription.

Authors:  Wei Qin; Fengmin Jiang; Tao Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2021-11-13       Impact factor: 2.629

3.  Exploring the Pharmacological Mechanism of the Effective Chinese Medicines Against Gynecological Cancer Based on Meta-Analysis Combined With Network Pharmacology Analysis.

Authors:  Ning Ren; Lulin Yu; Lihui Qian; Gewei Ye; Zhenzheng Zhu; Jieru Yu; Leitao Sun; Leyin Zhang
Journal:  Front Oncol       Date:  2022-07-06       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.